[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mgmt-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MGMT Gene",20,15,[8,16,23,30,37,43,49,55,61,67,72,78,84,90,96,102,109,115,122,129],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07025226","Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease",[12],"Early Phase 1","RECRUITING","2026-08-26T02:16:52.995882Z","2026-07-05T05:32:16.729507Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05864534","Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma",[20],"Phase 2","2026-08-26T02:17:27.435233Z","2026-05-05T02:43:29.529964Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05660369","CARv3-TEAM-E T Cells in Glioblastoma",[27],"Phase 1","2026-08-26T02:16:28.221034Z","2026-05-05T02:43:29.078350Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT05734560","D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients",[34],"Phase 1\u002FPhase 2","2026-08-26T02:17:21.315591Z","2026-05-05T02:43:28.883460Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT07343986","Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma",[27],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.826957Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06649851","G-CSF After Chemo-radiation in Patients With Glioblastoma",[20],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.531128Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT02977780","INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)",[20],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.965100Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05052957","hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)",[20],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:27.959629Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06177964","Lerapolturev (PVSRIPO) in GBM",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:27.815653Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":28,"content_modified":71},"NCT07326566","Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII",[20],"2026-05-05T02:43:27.420106Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07185880","A Phase 1\u002F2 Study of the Safety and Tolerability of MT-125 in GBM Patients",[34],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:27.322334Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05879250","WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",[20],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:26.920491Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06186401","Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2\u002FIL-13Ralpha2 CAR (E-SYNC) T Cells",[27],"2026-08-26T02:15:48.613507Z","2026-05-05T02:35:31.686467Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT04573140","A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)",[27],"2026-08-26T02:17:43.321968Z","2026-05-05T02:35:31.638718Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05691491","Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness",[34],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.203605Z",{"nct_id":103,"title":104,"phases":105,"status":106,"updated_at":107,"content_modified":108},"NCT07604285","A Phase 1\u002F2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma",[34],"NOT_YET_RECRUITING","2026-08-26T02:18:17.950264Z","2026-05-29T15:36:40.222679Z",{"nct_id":110,"title":111,"phases":112,"status":106,"updated_at":113,"content_modified":114},"NCT07708961","Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma",[20],"2026-08-26T02:15:27.567165Z","2026-07-19T19:36:05.093299Z",{"nct_id":116,"title":117,"phases":118,"status":119,"updated_at":120,"content_modified":121},"NCT06973096","CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T02:23:47.185024Z","2026-05-05T02:43:27.858881Z",{"nct_id":123,"title":124,"phases":125,"status":119,"updated_at":127,"content_modified":128},"NCT06388733","A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma",[126],"Phase 3","2026-08-03T03:19:09.261668Z","2026-05-05T02:43:27.602970Z",{"nct_id":130,"title":131,"phases":132,"status":119,"updated_at":133,"content_modified":134},"NCT03423628","A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",[27],"2026-08-03T03:23:54.120018Z","2026-05-05T02:43:27.393819Z"]